[
  {
    "ts": "2026-02-25T01:15:25+00:00",
    "headline": "Why Eli Lilly Stock Slumped Today",
    "summary": "Investors worried that the company could take quite a revenue hit due to a competitor's move.",
    "url": "https://www.fool.com/investing/2026/02/24/why-eli-lilly-stock-slumped-today/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "2e66560f-1dd1-3a2b-9f89-0b2c31ce3255",
      "content": {
        "id": "2e66560f-1dd1-3a2b-9f89-0b2c31ce3255",
        "contentType": "STORY",
        "title": "Why Eli Lilly Stock Slumped Today",
        "description": "",
        "summary": "Investors worried that the company could take quite a revenue hit due to a competitor's move.",
        "pubDate": "2026-02-25T01:15:25Z",
        "displayTime": "2026-02-25T01:15:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/0d11ab642e40bc0f6c99b7e07085c2ef",
          "originalWidth": 1400,
          "originalHeight": 683,
          "caption": "Person in lab gear looking through a microscope.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/etNdo1t.8L5zLK_gCH9c9Q--~B/aD02ODM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/0d11ab642e40bc0f6c99b7e07085c2ef.cf.webp",
              "width": 1400,
              "height": 683,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6VUVujFcQVXRmg3n5b7EtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/0d11ab642e40bc0f6c99b7e07085c2ef.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/24/why-eli-lilly-stock-slumped-today/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-stock-slumped-011525647.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T13:01:03+00:00",
    "headline": "Novo Nordisk's Loss Is Eli Lilly's Gain",
    "summary": "Eli Lilly and Company (NYSE:LLY) shares are up on Monday as the company benefits from positive market sentiment following Novo Nordisk A/S’ (NYSE:NVO) disappointing trial results for a weight-loss drug, adding pressure as broader markets edged lower. Eli Lilly Gains as Novo Nordisk Trial Setback Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands",
    "url": "https://finance.yahoo.com/news/novo-nordisks-loss-eli-lillys-130103846.html",
    "source": "Benzinga",
    "provider": "yfinance",
    "raw": {
      "id": "598577b8-c4ae-3908-af01-7676cb7d0216",
      "content": {
        "id": "598577b8-c4ae-3908-af01-7676cb7d0216",
        "contentType": "STORY",
        "title": "Novo Nordisk's Loss Is Eli Lilly's Gain",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) shares are up on Monday as the company benefits from positive market sentiment following Novo Nordisk A/S’ (NYSE:NVO) disappointing trial results for a weight-loss drug, adding pressure as broader markets edged lower. Eli Lilly Gains as Novo Nordisk Trial Setback Novo Nordisk’s stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly’s tirzepatide, marketed under the Zepbound and Mounjaro brands",
        "pubDate": "2026-02-25T13:01:03Z",
        "displayTime": "2026-02-25T13:01:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Benzinga/abbaaecb0fde99ee3964b9d76b965665",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IUU._bBhgVBKB51v8QU4QQ--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/abbaaecb0fde99ee3964b9d76b965665.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u28Izd0a40lCOZ5kJER0Ig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/abbaaecb0fde99ee3964b9d76b965665.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Benzinga",
          "url": "http://www.benzinga.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-loss-eli-lillys-130103846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisks-loss-eli-lillys-130103846.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T12:57:47+00:00",
    "headline": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
    "summary": "Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a “Meltdown Monday.” Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
    "url": "https://247wallst.com/investing/2026/02/25/here-are-wednesdays-top-wall-street-analyst-research-calls-abbvie-angel-studios-first-solar-ibm-kroger-molson-coors-oracle-workday-and-more/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "4169d733-42be-3151-835b-ba5bd346912c",
      "content": {
        "id": "4169d733-42be-3151-835b-ba5bd346912c",
        "contentType": "STORY",
        "title": "Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
        "description": "",
        "summary": "Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a “Meltdown Monday.” Stocks rallied on Tuesday, and all major indices closed higher. While not recouping all of the losses from Monday, a strong bounce-back was a welcome sight for investors. A combination of a rebound in technology ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: AbbVie, Angel Studios, First Solar, IBM, Kroger, Molson Coors, Oracle, Workday, and More",
        "pubDate": "2026-02-25T12:57:47Z",
        "displayTime": "2026-02-25T12:57:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/8338f370f249766d037be2988fc68cf3",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8oHqLvL4LSIh_k84TF28VQ--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/8338f370f249766d037be2988fc68cf3.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M2B5MfoEY0V7wX_NrqStUQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/8338f370f249766d037be2988fc68cf3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/25/here-are-wednesdays-top-wall-street-analyst-research-calls-abbvie-angel-studios-first-solar-ibm-kroger-molson-coors-oracle-workday-and-more/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wednesday-top-wall-street-analyst-125747007.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "TREX"
            },
            {
              "symbol": "KNSL"
            },
            {
              "symbol": "ENPH"
            },
            {
              "symbol": "OVV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "LYV"
            },
            {
              "symbol": "PFG"
            },
            {
              "symbol": "ANGX"
            },
            {
              "symbol": "FSLR"
            },
            {
              "symbol": "IBM"
            },
            {
              "symbol": "KR"
            },
            {
              "symbol": "ORCL"
            },
            {
              "symbol": "WDAY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T12:08:55+00:00",
    "headline": "Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low",
    "summary": "After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over the past year, now sitting near its 52-week low. As a result, Reddit sentiment has followed along with this downward shift, sliding from a quarterly average of 56 to a weekly average of 43 ... Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low",
    "url": "https://247wallst.com/investing/2026/02/25/novo-nordisk-cuts-wegovy-prices-in-half-while-its-stock-sits-near-a-52-week-low/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "dd10fce5-8ccc-35c8-be63-f4fbe3726787",
      "content": {
        "id": "dd10fce5-8ccc-35c8-be63-f4fbe3726787",
        "contentType": "STORY",
        "title": "Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low",
        "description": "",
        "summary": "After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over the past year, now sitting near its 52-week low. As a result, Reddit sentiment has followed along with this downward shift, sliding from a quarterly average of 56 to a weekly average of 43 ... Novo Nordisk Cuts Wegovy Prices in Half While Its Stock Sits Near a 52-Week Low",
        "pubDate": "2026-02-25T12:08:55Z",
        "displayTime": "2026-02-25T12:08:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/a0d3a0e2f4155ed8d8da3ce27eac142a",
          "originalWidth": 686,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rq76f8F0oZe4klQDn0Hnfw--~B/aD01MTI7dz02ODY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/a0d3a0e2f4155ed8d8da3ce27eac142a.cf.webp",
              "width": 686,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ALAZXFUT9E0wT0UGpJHY3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/a0d3a0e2f4155ed8d8da3ce27eac142a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/25/novo-nordisk-cuts-wegovy-prices-in-half-while-its-stock-sits-near-a-52-week-low/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-cuts-wegovy-prices-120855525.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T15:55:33+00:00",
    "headline": "Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, but the firm does not expect a meaningful impact on the US market. BofA views the move mainly as an effort to […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-seen-resilient-155533053.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "7fd8ecdb-4058-3842-bb6d-447cd3f48b1c",
      "content": {
        "id": "7fd8ecdb-4058-3842-bb6d-447cd3f48b1c",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is included among the Goldman Sachs Dividend Stocks: Top 14 Stock Picks. On February 24, BofA said Novo Nordisk’s decision to cut GLP-1 list prices may draw attention, but the firm does not expect a meaningful impact on the US market. BofA views the move mainly as an effort to […]",
        "pubDate": "2026-02-25T15:55:33Z",
        "displayTime": "2026-02-25T15:55:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6aY42asq7dEA24eM0JX3IQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8359URliL1_uJRGx4OlSUg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-seen-resilient-155533053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-seen-resilient-155533053.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BAC"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T15:41:01+00:00",
    "headline": "BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update",
    "summary": "BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unlikely to have any material impact on the U.S. market. BofA sees today’s move as an attempt to reduce copay/coinsurance costs to patients in settings where that figure is calculated of list/WAC price. More broadly, the firm thinks it’s fair for investors to wonder if/when commercial reimbursement of GLP-1’s could become more commonplace, wi",
    "url": "https://finance.yahoo.com/news/bofa-sees-limited-impact-eli-154101639.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "d4caadab-1e13-31b4-9a73-69920e4d4bdc",
      "content": {
        "id": "d4caadab-1e13-31b4-9a73-69920e4d4bdc",
        "contentType": "STORY",
        "title": "BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update",
        "description": "",
        "summary": "BofA says that today’s announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm’s view the update is unlikely to have any material impact on the U.S. market. BofA sees today’s move as an attempt to reduce copay/coinsurance costs to patients in settings where that figure is calculated of list/WAC price. More broadly, the firm thinks it’s fair for investors to wonder if/when commercial reimbursement of GLP-1’s could become more commonplace, wi",
        "pubDate": "2026-02-25T15:41:01Z",
        "displayTime": "2026-02-25T15:41:01Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/bofa-sees-limited-impact-to-eli-lillys-franchise-from-novos-glp-1-price-update-thefly-news",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZmeJPv9d6gKGE1bbiJoSwg--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_VlCSLzqaaBkrggeNUiouw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c4f6c07e08d4829fbea65fa26099a197.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bofa-sees-limited-impact-eli-154101639.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bofa-sees-limited-impact-eli-154101639.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T14:57:20+00:00",
    "headline": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
    "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
    "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "38db119c-9f44-3acf-9b13-4ff354235b4a",
      "content": {
        "id": "38db119c-9f44-3acf-9b13-4ff354235b4a",
        "contentType": "STORY",
        "title": "Large cap pharma defensive AI winner, says RBC as it backs Lilly & AbbVie",
        "description": "",
        "summary": "Investing.com -- RBC analysts say U.S. large cap pharma offers defensive exposure and earnings upside as artificial intelligence reshapes drug development.",
        "pubDate": "2026-02-25T14:57:20Z",
        "displayTime": "2026-02-25T14:57:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/large-cap-pharma-defensive-ai-145720870.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T13:40:00+00:00",
    "headline": "Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?",
    "summary": "LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.",
    "url": "https://finance.yahoo.com/news/lillys-glp-1-blockbusters-drive-134000159.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "da3801e1-b296-3e2d-af8a-50a86d85b86e",
      "content": {
        "id": "da3801e1-b296-3e2d-af8a-50a86d85b86e",
        "contentType": "STORY",
        "title": "Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?",
        "description": "",
        "summary": "LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.",
        "pubDate": "2026-02-25T13:40:00Z",
        "displayTime": "2026-02-25T13:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9080893d83d7b91adebaa73de0275743",
          "originalWidth": 620,
          "originalHeight": 412,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kr3Bs_6uAVDRozw9VQPkVw--~B/aD00MTI7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9080893d83d7b91adebaa73de0275743.cf.webp",
              "width": 620,
              "height": 412,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9WJ90kAb.RVRPdo0otQhsw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9080893d83d7b91adebaa73de0275743.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-glp-1-blockbusters-drive-134000159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-glp-1-blockbusters-drive-134000159.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T16:10:10+00:00",
    "headline": "Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is testing Omvoh (mirikizumab-mrkz) to treat Crohn’s disease and ulcerative colitis. ​The study found […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-releases-positive-161010431.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "4ae9479d-f342-37b5-92c2-b49db3b2cc29",
      "content": {
        "id": "4ae9479d-f342-37b5-92c2-b49db3b2cc29",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Buy and Hold For the Next 3 Years. On February 19, Eli Lilly and Company (NYSE:LLY) released positive results from the Phase 3 VIVID-2 open-label extension study. The study is testing Omvoh (mirikizumab-mrkz) to treat Crohn’s disease and ulcerative colitis. ​The study found […]",
        "pubDate": "2026-02-25T16:10:10Z",
        "displayTime": "2026-02-25T16:10:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/938248c8a9320fb817137488bd8f1e41",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.ShgphyEjRI8JO2PzEHLtw--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/938248c8a9320fb817137488bd8f1e41.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6J7sqlwgp7q.VQ6GgDvPbg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/938248c8a9320fb817137488bd8f1e41.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-releases-positive-161010431.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-releases-positive-161010431.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T14:45:03+00:00",
    "headline": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-144503100.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "43619948-3b4f-3081-ad18-afd205b7f8c0",
      "content": {
        "id": "43619948-3b4f-3081-ad18-afd205b7f8c0",
        "contentType": "STORY",
        "title": "Why Eli Lilly (LLY) is a Top Growth Stock for the Long-Term",
        "description": "",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "pubDate": "2026-02-25T14:45:03Z",
        "displayTime": "2026-02-25T14:45:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CWazdtIY_OpVNPwmJabcjQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/S8TA.VI0J48dh2TXqKSlJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-144503100.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-eli-lilly-lly-top-144503100.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T18:20:00+00:00",
    "headline": "1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash",
    "summary": "Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.",
    "url": "https://www.fool.com/investing/2026/02/25/1-reason-why-id-hold-this-weightloss-drug-leader/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7c875ec9-c682-343c-ae48-298c0bf3b8c6",
      "content": {
        "id": "7c875ec9-c682-343c-ae48-298c0bf3b8c6",
        "contentType": "STORY",
        "title": "1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash",
        "description": "",
        "summary": "Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes.",
        "pubDate": "2026-02-25T18:20:00Z",
        "displayTime": "2026-02-25T18:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/41153572dbd02e6ab3d1d0b5ac6d0933",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "A pharmacist helping a customer with a medicine prescription.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TXekhg7jR06NE0yudhfXsg--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/41153572dbd02e6ab3d1d0b5ac6d0933.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b46chCeiAG2wYWhR8fTJuQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/41153572dbd02e6ab3d1d0b5ac6d0933.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/25/1-reason-why-id-hold-this-weightloss-drug-leader/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-reason-why-id-hold-182000244.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "INTC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T20:13:00+00:00",
    "headline": "Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market",
    "summary": "CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized cancer centers, with price tags of up to $400,000 per treatment. For the millions of US patients with B-cell–driven autoimmune diseases like lupus, that model is not ...",
    "url": "https://www.thestreet.com/investing/stocks/eli-lilly-acquires-orna-therapeutics-for-2-4b-to-disrupt-car-t-market",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "71c3c648-dbb9-3888-bd45-5754325342f2",
      "content": {
        "id": "71c3c648-dbb9-3888-bd45-5754325342f2",
        "contentType": "STORY",
        "title": "Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market",
        "description": "",
        "summary": "CAR-T therapies have changed the oncology space, but their cost and complexity have confined these treatments to specialized cancer centers, with price tags of up to $400,000 per treatment. For the millions of US patients with B-cell–driven autoimmune diseases like lupus, that model is not ...",
        "pubDate": "2026-02-25T20:13:00Z",
        "displayTime": "2026-02-25T20:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/736620a120e40adbbc536cd4720f4c7b",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F_cqr7ObVav9uUsiftVcrg--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/736620a120e40adbbc536cd4720f4c7b.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vxESFjJPSwfyMp50xsym3Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/736620a120e40adbbc536cd4720f4c7b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/investing/stocks/eli-lilly-acquires-orna-therapeutics-for-2-4b-to-disrupt-car-t-market",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-acquires-orna-therapeutics-201300500.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T19:35:00+00:00",
    "headline": "Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.",
    "summary": "Eli Lilly has seen revenue and earnings soar in recent years.",
    "url": "https://www.fool.com/investing/2026/02/25/lilly-steps-forward-in-obesity-drug-market/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "658b736d-f690-3155-9697-67d5a1ae6eef",
      "content": {
        "id": "658b736d-f690-3155-9697-67d5a1ae6eef",
        "contentType": "STORY",
        "title": "Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.",
        "description": "",
        "summary": "Eli Lilly has seen revenue and earnings soar in recent years.",
        "pubDate": "2026-02-25T19:35:00Z",
        "displayTime": "2026-02-25T19:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/cc404da18b184a4b6ea018d0a085bd65",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "Two people look at something on a computer in an office.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2DYTig93jKne19epw_66rw--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/cc404da18b184a4b6ea018d0a085bd65.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YhjiqaLVFxoIIzRDP9k_7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/cc404da18b184a4b6ea018d0a085bd65.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/25/lilly-steps-forward-in-obesity-drug-market/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-just-took-2-193500658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-25T21:31:00+00:00",
    "headline": "NVIDIA Announces Financial Results for Fourth Quarter and Fiscal 2026",
    "summary": "NVIDIA corporate headquarters NVIDIA corporate headquarters in Silicon Valley Record quarterly revenue of $68.1 billion, up 20% from Q3 and up 73% from a year agoRecord quarterly Data Center revenue of $62.3 billion, up 22% from Q3 and up 75% from a year agoRecord full-year revenue of $215.9 billion, up 65% SANTA CLARA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ: NVDA) today reported record revenue for the fourth quarter ended January 25, 2026, of $68.1 billion, up 20% from the pre",
    "url": "https://finance.yahoo.com/news/nvidia-announces-financial-results-fourth-213100479.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "26209479-eb69-3140-bcb9-8567ff1d1b1e",
      "content": {
        "id": "26209479-eb69-3140-bcb9-8567ff1d1b1e",
        "contentType": "STORY",
        "title": "NVIDIA Announces Financial Results for Fourth Quarter and Fiscal 2026",
        "description": "",
        "summary": "NVIDIA corporate headquarters NVIDIA corporate headquarters in Silicon Valley Record quarterly revenue of $68.1 billion, up 20% from Q3 and up 73% from a year agoRecord quarterly Data Center revenue of $62.3 billion, up 22% from Q3 and up 75% from a year agoRecord full-year revenue of $215.9 billion, up 65% SANTA CLARA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ: NVDA) today reported record revenue for the fourth quarter ended January 25, 2026, of $68.1 billion, up 20% from the pre",
        "pubDate": "2026-02-25T21:31:00Z",
        "displayTime": "2026-02-25T21:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/2b1489d1fdde35ed7a18005285b1356c",
          "originalWidth": 1204,
          "originalHeight": 801,
          "caption": "NVIDIA corporate headquarters in Silicon Valley",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mr_JFWPehyOen3Nonx7vlg--~B/aD04MDE7dz0xMjA0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2b1489d1fdde35ed7a18005285b1356c.cf.webp",
              "width": 1204,
              "height": 801,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AHd.MqgFqhrp_bIJ4N3bbg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2b1489d1fdde35ed7a18005285b1356c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nvidia-announces-financial-results-fourth-213100479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nvidia-announces-financial-results-fourth-213100479.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "GROQ.PVT"
            },
            {
              "symbol": "CRWV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ANTH.PVT"
            },
            {
              "symbol": "INFY"
            },
            {
              "symbol": "TECHM.NS"
            },
            {
              "symbol": "WIT"
            },
            {
              "symbol": "CDNS"
            },
            {
              "symbol": "SIE.DE"
            },
            {
              "symbol": "SNPS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]